The Mosaic Company
MOS
$21.19
-5.57%
The Mosaic Company is a leading global producer and marketer of concentrated phosphate and potash crop nutrients, operating within the Agricultural Inputs industry. It is a dominant player with integrated operations, owning phosphate rock mines in the United States and potash mines in Canada, complemented by a major fertilizer distribution network in Brazil through its Mosaic Fertilizantes segment. The current investor narrative is heavily influenced by geopolitical supply shocks, as evidenced by recent news highlighting how the closure of the Strait of Hormuz has stranded a significant portion of global fertilizer supply, potentially creating a substantial margin opportunity for North American producers like Mosaic with localized supply chains, though this is juxtaposed against a challenging cyclical downturn in fertilizer prices.…
MOS
The Mosaic Company
$21.19
Investment Opinion: Should I buy MOS Today?
Rating: Hold. The core thesis is that Mosaic presents a high-risk, high-potential-reward cyclical value opportunity, but the timing of the cycle inflection remains too uncertain to warrant a Buy rating, especially given the recent analyst downgrades to neutral stances.
The evidence supports caution. While valuation is deeply discounted (P/E of 14.1x, P/B of 0.63x), this is justified by deteriorating fundamentals: revenue declined -7.55% YoY, gross margins are compressing, and free cash flow is deeply negative at -$534.6M. The forward P/E of 12.5x suggests only modest earnings recovery is priced in. The stock trades at a 60% discount to its 52-week high, reflecting the depth of the downturn but not necessarily an imminent rebound.
The thesis would upgrade to Buy on two conditions: 1) A sustained quarterly improvement in free cash flow turning positive, and 2) Concrete evidence of fertilizer price stabilization or recovery, likely reflected in expanding gross margins above 16%. It would downgrade to Sell if revenue decline accelerates beyond -10% YoY or if the stock breaks decisively below the $19.8 support level on high volume. Relative to its history and battered peers, the stock is fairly valued for the current depressed earnings environment but would be undervalued on a normalized mid-cycle basis.
Sign up to view all
MOS 12-Month Price Forecast
Mosaic is a classic late-cycle value trap vs. deep value opportunity. The weight of evidence currently favors the 'trap' narrative, with concrete financial metrics (negative FCF, margin compression) outweighing the allure of cheap multiples. The Hormuz event is a material wildcard that could accelerate a turnaround. The stance is neutral with medium confidence, as the direction hinges entirely on commodity prices, which are inherently unpredictable. We would upgrade to bullish on confirmation of two consecutive quarters of positive free cash flow generation and sequential gross margin expansion. A downgrade to bearish would be triggered by a breakdown below $19.8 with high volume, signaling a new leg down in the cycle.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on The Mosaic Company's 12-month outlook, with a consensus price target around $27.55 and implied upside of +30.0% versus the current price.
Average Target
$27.55
13 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
13
covering this stock
Price Range
$17 - $28
Analyst target range
The stock is covered by 13 analysts, indicating solid institutional interest. The consensus recommendation leans neutral to cautious, as evidenced by recent rating actions including downgrades from firms like B of A Securities (from Buy to Neutral) and Barclays (from Overweight to Equal Weight), reflecting a shift in sentiment amid the cyclical downturn. The average target price and implied upside cannot be calculated from the provided data, which only includes EPS and revenue estimates; however, the wide range of estimated EPS for the forward period, from a low of $1.85 to a high of $2.54, signals significant uncertainty and divergence in views on the company's earnings recovery trajectory, with the low target likely pricing in prolonged fertilizer price weakness and the high target anticipating a sharper rebound from current depressed levels.
Bulls vs Bears: MOS Investment Factors
The investment debate for Mosaic centers on a classic cyclical value play: deep valuation discounts and a potential geopolitical catalyst versus a severe, ongoing downturn in its core business. Currently, the bearish evidence appears stronger, as concrete financial deterioration (negative FCF, margin compression, revenue decline) outweighs the theoretical upside from valuation and supply shocks. The single most important tension is the timing and magnitude of the fertilizer price cycle rebound. If the Hormuz closure or other factors trigger a sharper-than-expected price recovery in 2024, the bull case of earnings normalization and multiple expansion becomes compelling. However, if the downturn persists through 2024, the deeply discounted multiples could prove justified, and the stock may remain range-bound or test new lows.
Bullish
- Deeply Discounted Valuation: Mosaic trades at a trailing P/E of 14.14x and a forward P/E of 12.48x, a significant discount to its historical highs and the broader market. Its Price-to-Book ratio of 0.633x and Price-to-Sales of 0.634x suggest the market is pricing in a severe cyclical trough, offering a substantial margin of safety if fertilizer prices rebound.
- Geopolitical Supply Shock Catalyst: Recent news highlights the closure of the Strait of Hormuz, which has stranded a third of global fertilizer supply. This creates a potential margin opportunity for North American producers like Mosaic with localized supply chains, providing a near-term catalyst for price and sentiment recovery.
- Strong Balance Sheet: The company maintains a healthy financial position with a debt-to-equity ratio of 0.437 and a current ratio of 1.315. This solid balance sheet provides resilience to weather the current cyclical downturn without significant financial distress.
- Analyst EPS Recovery Expectations: Analyst forward EPS estimates average $2.23, with a high estimate of $2.54, implying a significant earnings recovery from the recent Q4 EPS of $0.55. This forward-looking optimism, despite recent downgrades, suggests the market expects a cyclical rebound.
Bearish
- Severe Cyclical Downturn in Progress: Q4 2025 revenue declined 7.55% YoY to $2.60B, continuing a multi-quarter deceleration from peak cycle levels. Gross margin compressed sharply from 18.63% in Q1 2025 to 14.17% in Q4, demonstrating the severe pressure on fertilizer prices and profitability.
- Negative Free Cash Flow: Trailing twelve-month free cash flow is deeply negative at -$534.6 million. This indicates the company is burning cash and not generating sufficient internal funds for operations and capex, increasing reliance on its balance sheet during the downturn.
- Analyst Sentiment Turning Cautious: Recent analyst actions include downgrades from B of A Securities (Buy to Neutral) and Barclays (Overweight to Equal Weight). This shift reflects growing caution about the duration and depth of the fertilizer cycle downturn, capping near-term upside.
- Persistent Underperformance vs. Market: The stock has a 1-year relative strength of -62.1% versus the S&P 500, which gained 24.99%. This severe underperformance indicates sustained negative momentum and a lack of investor confidence in a near-term turnaround.
MOS Technical Analysis
The stock is entrenched in a pronounced downtrend, with a 1-year price change of -37.157%, significantly underperforming the S&P 500's 24.99% gain. The current price of $22.9 positions it near the lower end of its 52-week range, trading at approximately 60% of the distance between its 52-week low of $19.8 and high of $38.23, indicating deep oversold conditions that may present a value opportunity but also reflect persistent negative sentiment. Recent momentum shows a modest short-term bounce, with a 1-month price increase of 7.0093%, which contrasts sharply with the longer-term 3-month decline of -2.925%; this divergence suggests a potential oversold relief rally or mean reversion attempt, though it remains within the context of a broader bearish trend. Key technical support is firmly established at the 52-week low of $19.8, while resistance looms near the 52-week high of $38.23; a sustained breakdown below $19.8 would signal a new leg down, whereas reclaiming the $30 level would be necessary to suggest a trend reversal. The stock's beta of 0.808 indicates it has been about 20% less volatile than the broader market over the measured period, which is atypical for a cyclical materials stock and may reflect its depressed trading range and reduced speculative interest.
Beta
0.81
0.81x market volatility
Max Drawdown
-47.6%
Largest decline past year
52-Week Range
$20-$38
Price range past year
Annual Return
-41.9%
Cumulative gain past year
| Period | MOS Return | S&P 500 |
|---|---|---|
| 1m | -11.3% | -1.3% |
| 3m | -20.2% | +14.0% |
| 6m | -12.0% | +9.5% |
| 1y | -41.9% | +20.9% |
| ytd | -15.3% | +9.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MOS Fundamental Analysis
Revenue is under significant pressure, with the most recent Q4 2025 revenue of $2.603 billion representing a -7.55% year-over-year decline, continuing a multi-quarter trend of deceleration from the peak cycle; segment data shows the Phosphates segment ($1.015B) and Mosaic Fertilizantes ($1.146B) as the largest contributors, with the Potash segment ($681M) being the smallest, indicating broad-based softness across business lines. The company remains profitable but with compressed margins, posting Q4 net income of $162.2 million and a gross margin of 14.17%, which is down substantially from the 18.63% gross margin in Q1 2025, highlighting severe margin contraction as fertilizer prices have fallen from cyclical highs. The balance sheet is relatively healthy but cash flow generation has turned negative; the debt-to-equity ratio is a manageable 0.437 and the current ratio is a solid 1.315, but trailing twelve-month free cash flow is deeply negative at -$534.6 million, indicating the company is not currently generating sufficient internal cash to fund operations and capital expenditures, potentially increasing reliance on its balance sheet.
Quarterly Revenue
$2.6B
2025-12
Revenue YoY Growth
-0.07%
YoY Comparison
Gross Margin
+0.14%
Latest Quarter
Free Cash Flow
$-534600000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MOS Overvalued?
Given net income is positive, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is 14.14x, while the forward PE is 12.48x; the lower forward multiple suggests the market anticipates some earnings recovery, but the modest gap implies expectations remain tempered. Compared to sector averages, Mosaic trades at a significant discount; its trailing PE of 14.14x is below the typical range for commodity producers during stable periods, and its Price-to-Sales ratio of 0.634x and Price-to-Book ratio of 0.633x are deeply discounted, reflecting pessimism around the cyclical downturn and near-term earnings power. Historically, the stock's valuation is near multi-year lows; its current PB ratio of 0.633 is substantially below its historical highs above 2.0 seen in early 2022, and its PE ratio is also at the lower end of its historical range, suggesting the market is pricing in a severe cyclical trough and offering a potential margin of safety if the cycle inflects.
PE
14.2x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -702x~58x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
4.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are pronounced, centered on cash burn and margin pressure. The company's negative TTM free cash flow of -$534.6 million is a critical concern, indicating it is consuming rather than generating cash during the downturn. Gross margin has contracted by over 450 basis points in just three quarters, from 18.63% to 14.17%, exposing vulnerability to further fertilizer price declines. While the balance sheet is currently stable (D/E of 0.44), prolonged negative FCF would erode this strength.
Market & Competitive Risks stem from its pure-play cyclicality and valuation compression. The stock's 37.2% annual decline and trading near 52-week lows reflect the market's harsh pricing of the downturn. Its beta of 0.808, lower than typical for materials, may indicate reduced speculative interest but offers little downside protection in a broader market sell-off. The primary risk is that the current discounted valuation (P/B of 0.63) becomes the new normal if the cycle trough is longer than anticipated, preventing multiple expansion even if earnings stabilize.
The Worst-Case Scenario involves a prolonged global agricultural slowdown combined with the resolution of geopolitical supply disruptions, leading to sustained fertilizer price weakness. This could drive quarterly losses, force dividend cuts (current yield 3.67%), and lead to credit rating pressure. The realistic downside is a retest and break below the recent 52-week low of $19.82. From the current price near $22.9, this implies a potential loss of approximately -13%. A more severe scenario, aligning with the stock's maximum drawdown of -47.6%, could see prices fall toward the $16-$18 range if the cycle mirrors prior depths, representing a -20% to -30% decline.
FAQ
The key risks are, in order of severity: 1) Cycommodity Price Risk: Further declines in phosphate and potash prices would compress margins further from the already-low 14.2% gross margin. 2) Cash Flow Risk: The company is burning cash (-$534.6M TTM FCF), which could pressure the balance sheet and the 3.67% dividend if prolonged. 3) Macroeconomic Risk: A global slowdown could reduce agricultural demand and farm incomes, extending the cycle downturn. 4) Geopolitical Resolution Risk: If the Strait of Hormuz reopens quickly, the supply-driven price support evaporates. The stock's 37% annual decline demonstrates these risks are actively being priced in.
The 12-month forecast is highly bifurcated, with a base case target of $26-$30 (50% probability), a bull case of $34-$38 (30% probability), and a bear case of $19-$22 (20% probability). The base case is most likely, assuming the fertilizer cycle finds a bottom but does not sharply rebound, with earnings stabilizing near the analyst average of $2.23. The key assumption behind this view is that the severe margin compression seen in recent quarters halts, allowing the deeply discounted valuation to provide a floor for the stock price. The wide range reflects the high uncertainty inherent in commodity cycles.
MOS is fairly valued to slightly undervalued relative to its current depressed earnings but deeply undervalued on a normalized mid-cycle basis. Its trailing P/E of 14.1x and forward P/E of 12.5x are low, but justified by negative free cash flow and margin compression. The extreme discounts on Price-to-Book (0.63x) and Price-to-Sales (0.63x) suggest the market is pricing in a severe trough, implying significant upside if earnings recover. The valuation implies the market expects the current cyclical downturn to persist, with no near-term catalyst for a sharp rebound. Compared to its own history (P/B has been above 2.0), it is cheap, but it may remain cheap until the cycle inflects.
MOS is a speculative buy only for investors with a high risk tolerance and a long-term horizon who are betting on a fertilizer cycle recovery. The stock trades at deep valuation discounts (P/B 0.63x) and has a potential geopolitical catalyst from the Hormuz closure. However, it is not a good buy for most investors currently due to severe fundamental headwinds, including a -7.55% revenue decline, negative free cash flow of -$534.6M, and recent analyst downgrades. The risk/reward is asymmetric but skewed toward requiring patience; it could be a good buy on further weakness near the $20 support level for those willing to wait 2-3 years for the cycle to turn.
MOS is strictly a long-term investment for patient capital, with a suggested minimum holding period of 3-5 years to potentially ride a full commodity cycle. It is unsuitable for short-term trading due to its low beta (0.808), dependence on slow-moving agricultural fundamentals, and high volatility around earnings driven by unpredictable fertilizer prices. The stock does not offer stable growth or reliable income for the short term, as its dividend could be cut if cash burn continues. Long-term investors are betting on the eventual mean reversion of fertilizer prices and the company's low-cost asset base, a thesis that will take years to play out.